**INN** | Amikacin  
---|---  
**ATC codes** | J01GB06  
**Medicine type** | Chemical agent  
**Antibiotic groups** | ACCESS  
**EML status history**
- First added in 1999 (TRS 895) for *Multi-drug resistant Mycobacterium tuberculosis*
- Added in 2017 (TRS 1006) for *Sepsis without septic shock*
- Added in 2017 (TRS 1006) for *Neutropenia*
- Added in 2017 (TRS 1006) for *Acute pyelonephritis*
- Added in 2017 (TRS 1006) for *Inflammatory and other diseases of prostate*
- Changed in 2021 for *Infectious blepharitis*  
**Therapeutic equivalent for**
- gentamicin for *Infectious blepharitis*  
**Wikipedia** | Amikacin  
**DrugBank** | Amikacin

---

**Recommendations**
### Access group antibiotics

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

#### Indications

**First choice**

- Neutropenia (high-risk)
- co-prescribed with cefotaxime
  - Inflammatory and other diseases of prostate (severe)
- co-prescribed with cefotaxime
  - Acute pyelonephritis (severe)
- co-prescribed with ceftriaxone
  - Inflammatory and other diseases of prostate (severe)
- co-prescribed with ceftriaxone
  - Acute pyelonephritis (severe)

**Second choice**

- co-prescribed with cloxacillin
  - Sepsis without septic shock

### Antituberculosis medicines

Parenteral > General injections > unspecified: 100 mg per 2 mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate)

#### Indications

- Multi-drug resistant Mycobacterium tuberculosis